The total Chinese pharmaceutical market had reached RMB 828.36 billion (US$ 120.84 billion, at an exchange rate of US $1 = RMB 6.83) with an annual growth rate (AGR) of 26.50% in 2008. The growth rate, as well as the absolute size of the rapidly-expanding Chinese pharmaceutical market, is no doubt astonishing. The categorization of the Chinese pharmaceutical market as one of the “emerging pharmaceutical market” may need to be reconsidered.
Even though the current Chinese pharmaceutical market is still mainly a generic market, many of the innovative drugs have been rapidly up-taken by large Chinese hospitals in major cities. Some of the highly-priced oncology drugs, for example, erlotinib and trastuzumab, have made into the list of top 20 cancer drugs (by sales) in the last few years.
Many pharmaceutical companies have realized that just locking their eyes at the “mature” pharmaceutical markets (US, Europe and Japan) is no longer enough to sustain growth, especially for the future growth.
This Second Edition of the China Pharma Executive Summary provides hospital drug utilization data for 14 key therapeutic areas, including asthma, cancer, liver diseases, diabetes, hypertension, depression, allergy, dementia, benign prostate hyperplasia (BPH), ophthalmology, hyperlipoidemia, rheumatoid arthritis, dermatosis, and blood products, etc.
Key contents include:
2008 annual drug sales in the Chinese hospital market for each therapeutic area*.
Sales and market shares of top 20 manufacturers in each therapeutic area.
Sales and market shares of top drugs in each therapeutic area.
Annual drug sales in each of the eight therapeutic areas (cancer, blood diseases, liver diseases, dermatosis, hypertension, diabetes, dementia, and hyperlipidemics) had passed US $1 billion in 2008. Sales of cancer drugs in the Chinese hospital market reached US $4.612 billion, followed immediately by blood products which had US $3.966 billion in 2008. Except skin disease, eye disease, allergy and BPH, drug sales in all other therapeutic areas had achieved double digit growth rates in 2008. *: Drug prices are based on the hospital drug purchase prices in 2008 for all drug utilization data in this report.
(0 items)
